SkinnyRx Tirzepatide Review: The Real Price, a Tirzepatide Tablet & Honest Verdict (2026)

SkinnyRx sells something most of this field does not: a once-daily compounded tirzepatide tablet, priced identically to the weekly injection. It also advertises that tirzepatide "from $299 / month" on its homepage, on both treatment pages and on its own shop page — and $299 is not what a month of it costs. Read from SkinnyRx's own pricing bundle and confirmed in its plan selector, $299 is the twelve-month rung. Month to month, the same tirzepatide is $399. SkinnyRx also has an FDA warning letter on record, dated February 2026, which we disclose below and everywhere else we link to the company. Every fact here comes from the company's own published program and the FDA's own published letter.

What SkinnyRx actually costs

Every price SkinnyRx advertises is the bottom of a term ladder. Its shop page publishes the whole ladder as a plan selector, and its own front-end pricing data carries the same four rungs, so this is not an inference — it is the company's own table:

So the honest month-to-month figure for compounded tirzepatide at SkinnyRx — injection or tablet, the price is the same either way — is $399/month. Getting to the advertised $299 costs a twelve-month commitment, and SkinnyRx's own refund policy states that canceling inside a committed term can see the discount "reversed or proportionally adjusted," so the cheaper rung is not a price you can take and then leave. Compounded injectable semaglutide follows the identical shape: $349/month month to month against an advertised $199. This is the figure our price index and our cheapest-tirzepatide ranking file, because a prepay rate sorted as a monthly one puts a program dozens of places above where a reader would actually find it.

One thing worth knowing before you compare menus: the Wegovy® Pill and the Foundayo™ Pill (orforglipron) are both displayed on the SkinnyRx homepage marked "Unavailable." They are advertised, not obtainable. There is no brand-name tirzepatide pathway here at all — no Zepbound, no Mounjaro — so the compounded route is the only route.

The tirzepatide tablet, which is the actual reason to look

Most compounded telehealth sells one route: a weekly subcutaneous injection. SkinnyRx sells a once-daily oral tirzepatide tablet at the same price as the injection, with a microdose line available on both. On a site about tirzepatide specifically, that is the differentiator worth naming — and it is priced without the premium several competitors charge for going needle-free. What does not exist is published evidence on how a compounded oral tirzepatide absorbs; the pivotal trials were run on the injected brand molecule, and an oral compounded copy was not the product tested. Treat the route as a convenience choice you should discuss with the prescriber, not as an established equivalent.

The brand-vs-compounded question

SkinnyRx dispenses compounded tirzepatide only, not the FDA-approved branded product. Compounded tirzepatide is pharmacy-made, not itself an FDA-approved finished drug, and was not the specific product studied in the pivotal trials. SkinnyRx publishes that caveat itself, on the same screen as its product cards. See our guide to whether compounded tirzepatide is still legal in 2026 for the regulatory picture, and our Zepbound cost and savings guide for the branded benchmark you cannot buy here.

FDA warning letter, February 2026

FDA issued Lean Rx, Inc. dba SkinnyRx a warning letter in February 2026, posted under the subject line False & Misleading Claims/Misbranded (Telehealth)³. We confirmed it against FDA's own published warning-letter record rather than repeating a second-hand report, and the reference at the foot of this page links straight to FDA's copy.

We are not going to paraphrase FDA's findings back to you — the letter is short, it is public, and reading the agency's own words beats reading ours. What matters for how you use this page is that the letter exists, that it is recent, and that we are telling you about it while still linking to SkinnyRx on commission. The affiliate relationship has not changed the ranking and has not been quietly adjusted around the letter; the notice travels with SkinnyRx on every ranking, index and card where we link to the company, not just here.

How the care model holds up

SkinnyRx's real strengths: the oral tirzepatide tablet at injection parity, consultation and free overnight shipping bundled into the monthly price, both compounded semaglutide and tirzepatide with a microdose line on each, Affirm financing, a 90-day money-back guarantee, unlimited provider messaging and cancel-anytime. The trade-offs are real: the advertised price is a twelve-month rate and the month-to-month figure is $100 higher, canceling inside a committed term can claw the discount back, states served are not publicly disclosed and sit behind the intake, two of the five products on its own menu are marked Unavailable, and there is a warning letter on the record. As with any GLP-1 program, tirzepatide carries labeled warnings for acute pancreatitis, gallbladder disease, and a boxed thyroid C-cell tumor warning — see our guides on Zepbound side effects, the gallbladder risk, and the thyroid cancer warning.

Does the drug work? (Separate from the provider)

Judge the provider on price, oversight and disclosure; judge the molecule on its trials. Tirzepatide's are strong — roughly 15–21% of body weight over 72 weeks in SURMOUNT-1¹, and better than semaglutide head-to-head² — but they were run on the brand drug at FDA-approved doses. Our tirzepatide evidence guide has the full picture.

The honest verdict

SkinnyRx is worth a look for one specific reason — a compounded tirzepatide tablet at the same price as the injection, which most providers here simply does not sell. Go in knowing two things it does not lead with: the price it advertises is a twelve-month commitment rate, and it has an FDA warning letter from February 2026 that you should read at fda.gov yourself. If a clean regulatory record matters more to you than the oral route, compare it against ShedRx or CoreAge Rx. SkinnyRx isn't the only provider here with a confirmed FDA warning letter citing near-identical misbranding language — see our Belle Health review for the other one. On a related note about GLP-1-adjacent marketing that doesn't hold up under scrutiny, see our AmberHealth entry — it isn't a tirzepatide source at all. Not every warning-letter claim survives a check, either: this site once carried an unconfirmed one against Fierce Health, and the same company-column match against FDA's full index that returned SkinnyRx's letter returned nothing for Fierce Health. That claim has been withdrawn and the correction published on its own review. For a provider with genuinely named, board-certified physicians instead, see Heros Health. Another provider this review's own live check was blocked from reaching, this time by a Cloudflare wall rather than confirming anything either way, is Neo Soma Healthcare. See our best tirzepatide providers ranking for the full field.